Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11080013 | 0.98 | APEX1 (0.42) | APEX1HTTALDH1A1GAAKDM4E | |
| SCHEMBL1008027 | 0.89 | CYP3A4 (0.50) | APEX1HTTALDH1A1GAAKDM4E | |
| SCHEMBL24404192 | 0.88 | B3GNT2 (0.38) | APEX1HTTALDH1A1GAAKDM4E | |
| SCHEMBL295471 | 0.84 | HTT (0.46) | APEX1HTTALDH1A1HSD17B10CYP3A4 | |
| SCHEMBL1247958 | 0.83 | ALDH1A1 (0.37) | APEX1HTTALDH1A1GAAKDM4E | |
| SCHEMBL11187717 | 0.77 | HTT (0.42) | HTTALDH1A1GAAKDM4EHSD17B10 | |
| SCHEMBL22899016 | 0.76 | HTT (0.41) | HTTALDH1A1GAAKDM4EHSD17B10 | |
| SCHEMBL22899017 | 0.76 | HTT (0.41) | HTTALDH1A1GAAKDM4EHSD17B10 | |
| SCHEMBL19722541 | 0.76 | HTT (0.43) | HTTALDH1A1GAAKDM4EHSD17B10 | |
| SCHEMBL23768669 | 0.76 | HTT (0.41) | APEX1HTTALDH1A1GAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3780226-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | Mitsubishi Chemical Corporation (JP) | 2021-02-17 | — | — | EP | disclosed |
| US-20210020991-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2021-01-21 | — | — | US | disclosed |
| EP-3310766-B1 | HYBRID SCORCH RETARDANT/CURE CO-AGENT | DOW GLOBAL TECHNOLOGIES LLC (US) | 2020-05-06 | — | — | EP | disclosed |
| US-10640474-B2 | Hybrid scorch retardant/cure co-agent | DOW GLOBAL TECHNOLOGIES LLC (US) | 2020-05-05 | — | — | US | disclosed |
| US-20180148421-A1 | Hybrid Scorch Retardant/Cure Co-Agent | DOW CHEMICAL (CHINA) INVESTMENT COMPANY LIMITED (CN) | 2018-05-31 | — | — | US | disclosed |
| US-20180148421-A1 | Hybrid Scorch Retardant/Cure Co-Agent | DOW CHEMICAL (CHINA) INVESTMENT COMPANY LIMITED (CN) | 2018-05-31 | — | — | US | disclosed |
| WO-2016201616-A1 | HYBRID SCORCH RETARDANT/CURE CO-AGENT | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148421-A1 | Hybrid Scorch Retardant/Cure Co-Agent | BCOR, RCOR1, RCOR3 | APEX1 125/4885HTT 916/4885ALDH1A1 225/4885 |
| US-10640474-B2 | Hybrid scorch retardant/cure co-agent | BCOR, RCOR1, RCOR3 | APEX1 125/4885HTT 916/4885ALDH1A1 225/4885 |
| US-20210020991-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | SLC9B2, SLC9A1, SLC9A2 | APEX1 536/4885HTT 4397/4885ALDH1A1 3675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.